| Monitoring Replication Protein A (RPA) dynamics in homologous recombination through site-specific incorporation of non-canonical amino acids N Pokhrel, S Origanti, EP Davenport, D Gandhi, K Kaniecki, RA Mehl, ... Nucleic acids research 45 (16), 9413-9426, 2017 | 47 | 2017 |
| Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells DM Gandhi, MW Majewski, R Rosas Jr, K Kentala, TJ Foster, E Greve, ... Bioorganic & medicinal chemistry 26 (9), 2514-2529, 2018 | 24 | 2018 |
| Synthetic analogues of the snail toxin 6-bromo-2-mercaptotryptamine dimer (BrMT) reveal that lipid bilayer perturbation does not underlie its modulation of voltage-gated … C Dockendorff, DM Gandhi, IH Kimball, KS Eum, R Rusinova, ... Biochemistry 57 (18), 2733-2743, 2018 | 23 | 2018 |
| Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist AE Moritz, RB Free, WS Weiner, EO Akano, D Gandhi, A Abramyan, ... Journal of medicinal chemistry 63 (10), 5526-5567, 2020 | 19 | 2020 |
| Design and evaluation of heterobivalent PAR1–PAR2 ligands as antagonists of calcium mobilization MW Majewski, DM Gandhi, R Rosas Jr, R Kodali, LA Arnold, ... ACS medicinal chemistry letters 10 (1), 121-126, 2018 | 18 | 2018 |
| The parmodulin NRD-21 is an allosteric inhibitor of PAR1 Gq signaling with improved anti-inflammatory activity and stability DM Gandhi, R Rosas Jr, E Greve, K Kentala, DRD N'Guessan, VA Snyder, ... Bioorganic & medicinal chemistry 27 (17), 3788-3796, 2019 | 10 | 2019 |
| Synthesis and initial pharmacology of dualtargeting ligands for putative complexes of integrin αVβ3 and PAR2 HWCD Mark W. Majewski, Disha M. Gandhi, Trudy Holyst, Zhengli Wang, Irene ... RSC Med. Chem, 940-949, 2020 | 3 | 2020 |
| NMR structural analysis of isolated shaker voltage-sensing domain in LPPG micelles H Chen, J Pan, DM Gandhi, C Dockendorff, Q Cui, B Chanda, ... Biophysical Journal 117 (2), 388-398, 2019 | 3 | 2019 |
| Synthesis and Initial Pharmacology of Heterobivalent Ligands Targeting Putative Complexes of Integrin αVβ3 and PAR2 M Majewski, D Gandhi, T Holyst, Z Wang, I Hernandez, R Rosas Jr, ... | 1 | 2019 |
| Discovery, Characterization, and Optimization of a Novel Positive Allosteric Modulator-Antagonist of the D3 Dopamine Receptor KK Snyder, AE Moritz, N Madaras, F Wang, A Kelley, D Gandhi, E Akano, ... Journal of Pharmacology and Experimental Therapeutics 389 (S3), 2024 | | 2024 |
| Structure–Activity Relationships of a Brain-Penetrant D3 Dopamine Receptor Negative Allosteric Modulator and Investigation of its Binding Site AE Moritz, NS Madaras, LR Inbody, AM Kelley, DM Gandhi, EO Akano, ... Journal of Pharmacology and Experimental Therapeutics 385 (S3), 2023 | | 2023 |
| Heterocyclic ligands of PAR1 and methods of use C Dockendorff, DM Gandhi, R Rosas US Patent 11,130,743, 2021 | | 2021 |
| Heterocyclic ligands of par1 and methods of use C DOCKENDORFF, DM GANDHI, JR ROSAS | | 2020 |
| Structure‐Activity Relationships of a Negative Allosteric Modulator of the D3 Dopamine Receptor and Investigation of its Binding Site AE Moritz, LR Inbody, DM Gandhi, E Akano, C Fearce, RB Free, ... The FASEB Journal 34 (S1), 1-1, 2020 | | 2020 |
| Strategies for the Modulation of Protease Activated Receptors (PARs) DM Gandhi | | 2018 |
| Lipid Bilayer Perturbation by the Snail Toxin 6-Bromo-2-Mercaptotryptamine Dimer does not Account for its Modulation of Voltage-Gated Potassium Channels C Dockendorff, D Gandhi, I Kimball, KS Eum, R Rusinova, H Ingólfsson, ... Biophysical Journal 112 (3), 246a-247a, 2017 | | 2017 |
| Supporting Information Design and Evaluation of Heterobivalent PAR1–PAR2 Ligands as Antagonists of Calcium Mobilization. MW Majewski, DM Gandhi, R Rosas Jr, C Dockendorff | | |
